Abbott Laboratories $ABT Shares Bought by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P raised its stake in Abbott Laboratories (NYSE:ABT) by 37.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 47,552 shares of the healthcare product maker’s stock after purchasing an additional 12,939 shares during the quarter. Loomis Sayles & Co. L P’s holdings in Abbott Laboratories were worth $6,468,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Skandinaviska Enskilda Banken AB publ lifted its holdings in shares of Abbott Laboratories by 1.2% during the second quarter. Skandinaviska Enskilda Banken AB publ now owns 369,066 shares of the healthcare product maker’s stock worth $50,197,000 after purchasing an additional 4,551 shares during the period. Norges Bank acquired a new position in Abbott Laboratories in the 2nd quarter valued at $3,026,180,000. Level Four Advisory Services LLC raised its position in Abbott Laboratories by 5.9% during the 2nd quarter. Level Four Advisory Services LLC now owns 20,910 shares of the healthcare product maker’s stock worth $2,844,000 after buying an additional 1,158 shares during the last quarter. Bank of Nova Scotia Trust Co. lifted its stake in shares of Abbott Laboratories by 16.8% in the 2nd quarter. Bank of Nova Scotia Trust Co. now owns 38,218 shares of the healthcare product maker’s stock worth $5,198,000 after acquiring an additional 5,500 shares during the period. Finally, Clarkston Capital Partners LLC boosted its holdings in shares of Abbott Laboratories by 15.1% in the second quarter. Clarkston Capital Partners LLC now owns 6,842 shares of the healthcare product maker’s stock valued at $931,000 after acquiring an additional 900 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

ABT opened at $128.11 on Tuesday. Abbott Laboratories has a 1-year low of $110.86 and a 1-year high of $141.23. The stock has a market cap of $222.77 billion, a P/E ratio of 16.05, a P/E/G ratio of 2.36 and a beta of 0.68. The stock’s 50 day simple moving average is $129.23 and its 200 day simple moving average is $131.04. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.30. The firm had revenue of $11.37 billion during the quarter, compared to analysts’ expectations of $11.40 billion. Abbott Laboratories had a return on equity of 17.78% and a net margin of 31.88%.Abbott Laboratories’s revenue was up 6.9% on a year-over-year basis. During the same period in the previous year, the firm posted $1.21 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. As a group, equities analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 17th. Investors of record on Wednesday, October 15th were paid a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend was Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio is presently 29.57%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on ABT shares. Jefferies Financial Group raised their price objective on shares of Abbott Laboratories from $145.00 to $149.00 and gave the company a “buy” rating in a research report on Thursday, October 16th. The Goldman Sachs Group boosted their target price on Abbott Laboratories from $153.00 to $157.00 and gave the stock a “buy” rating in a research report on Wednesday, October 1st. Benchmark assumed coverage on Abbott Laboratories in a report on Friday, October 10th. They issued a “buy” rating and a $145.00 price target for the company. Sanford C. Bernstein lifted their price target on Abbott Laboratories from $145.00 to $150.00 and gave the company an “outperform” rating in a research note on Thursday, October 16th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $147.00 price objective on shares of Abbott Laboratories in a research report on Thursday, October 16th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and an average price target of $147.00.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.